Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
Patient in their 60s with TP53 mutation by NGS, treated 12 years ago with FCR, then at first relapse 2 years ago started ibrutinib. Bone marrow biopsy performed upon progression while still on ibrutinib demonstrated > 9 chromosomal abnormalities on karyotype, but no dysplatic morphology to suggest MDS.
Community PollStarted
When do you test NGS for resistance mutations (such as PLCG2, BTK) in patients with CLL?
23 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · UPMC Hillman Cancer Center
Answered on
In this patient, the finding of a TP53 mutation trumps all, including complex karyotype. In the absence of TP53 mutation or deletion of 17p13.1 (the TP53 locus) on FISH, complex karyotype of 5 or greater abnormalities is generally associated with shorter time to treatment and PFS on both chemoimmuno...
Join for free or sign in to see the full answer